This company listing is no longer active
LMDX.F Stock Overview
Operates as a point of care diagnostics company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LumiraDx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.31 |
| 52 Week Low | US$0.000001 |
| Beta | 269.05 |
| 1 Month Change | 900.00% |
| 3 Month Change | 1,900.00% |
| 1 Year Change | -88.89% |
| 3 Year Change | -99.89% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower
Dec 20
LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors
Apr 17What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today
Nov 16Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022
Aug 20LumiraDx GAAP EPS of -$0.58, revenue of $44.7M
Aug 18Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx
Jul 15Shareholder Returns
| LMDX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.4% |
| 1Y | -88.9% | 10.5% | 24.8% |
Return vs Industry: LMDX.F underperformed the US Medical Equipment industry which returned 32.6% over the past year.
Return vs Market: LMDX.F underperformed the US Market which returned 38.9% over the past year.
Price Volatility
| LMDX.F volatility | |
|---|---|
| LMDX.F Average Weekly Movement | 4,984.9% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LMDX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LMDX.F's weekly volatility has increased from 2123% to 4985% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,210 | Veronique Ameye | www.lumiradx.com |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx Limited Fundamentals Summary
| LMDX.F fundamental statistics | |
|---|---|
| Market cap | US$3.59m |
| Earnings (TTM) | -US$338.03m |
| Revenue (TTM) | US$126.52m |
0.0x
P/S Ratio0.0x
P/E RatioIs LMDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMDX.F income statement (TTM) | |
|---|---|
| Revenue | US$126.52m |
| Cost of Revenue | US$131.23m |
| Gross Profit | -US$4.71m |
| Other Expenses | US$333.32m |
| Earnings | -US$338.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -3.73% |
| Net Profit Margin | -267.19% |
| Debt/Equity Ratio | -201.0% |
How did LMDX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/28 10:41 |
| End of Day Share Price | 2024/10/28 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LumiraDx Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Vijay Kumar | Evercore ISI |
| Matthew Sykes | Goldman Sachs |